+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Drugs Market by Indication, Drug Class, Route of Administration, Treatment Modality, Drug Type, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Brain Cancer Drugs Market by Indication, Drug Class, Route of Administration, Treatment Modality, Drug Type, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Brain Cancer Drugs Market by Indication, Drug Class, Route of Administration, Treatment Modality, Drug Type, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011104
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Cancer Drugs Market is projected to reach USD 2.52 Billion in 2026. It is expected to continue growing at a CAGR of 8.05%, reaching USD 4.03 Billion by 2032.

Brain cancer drugs are moving from a historically cytotoxic, surgery-adjuvant model toward biomarker-guided oncology that combines alkylating agents, targeted therapies, immuno-oncology, tumor treating fields, radiopharmaceutical concepts, and precision trial designs. Glioblastoma remains the most aggressive primary malignant brain tumor in adults, while pediatric and lower-grade gliomas increasingly require molecular stratification to guide therapy selection.

The commercial and clinical focus is being shaped by high unmet need, limited blood-brain barrier penetration, tumor heterogeneity, and recurrence after standard-of-care therapy. Verified regulatory milestones underscore the shift: temozolomide remains central in newly diagnosed glioblastoma, tumor treating fields are FDA-authorized for glioblastoma, targeted combinations such as dabrafenib plus trametinib have expanded options for BRAF V600E-mutant glioma, and vorasidenib received FDA approval in 2024 for IDH-mutant grade 2 astrocytoma or oligodendroglioma after surgery.

Transformative Shifts in the Brain Cancer Drug Landscape

The brain cancer drugs landscape is being transformed by molecular diagnostics, adaptive clinical trials, and therapies designed around tumor biology rather than histology alone. The 2021 WHO Classification of Tumors of the Central Nervous System reinforced the importance of IDH mutation, 1p/19q codeletion, H3 K27 alterations, MGMT promoter methylation, and other markers in diagnosis and treatment planning.

Drug developers are prioritizing blood-brain barrier optimization, central nervous system pharmacokinetics, and combination regimens that can overcome immune suppression in the tumor microenvironment. The market is also seeing renewed interest in peptide vaccines, oncolytic viruses, checkpoint combinations, antibody-drug conjugates, PARP inhibitors, IDH inhibitors, and radiotherapy-sensitizing approaches, supported by growing genomic testing adoption in major oncology centers.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across discovery, diagnosis, trial design, and treatment monitoring in brain cancer drugs. AI-enabled radiomics can help quantify tumor volume, edema, necrosis, pseudoprogression, and treatment response from MRI, while digital pathology models are improving tumor grading support and biomarker interpretation when paired with expert review.

In drug development, machine learning is being used to screen compounds for CNS penetration, predict resistance pathways, identify patient subgroups, and optimize adaptive trial enrollment. Its most immediate value lies in reducing development inefficiency: brain cancer trials often struggle with small eligible populations, rapid progression, and imaging complexity, and AI can improve site selection, eligibility matching, longitudinal response assessment, and real-world evidence generation.

Key Regional Insights

North America leads in brain cancer drug development because of dense neuro-oncology networks, FDA orphan drug incentives, National Cancer Institute-supported research, and strong adoption of molecular testing. The United States remains the anchor market for first launches, while Canada contributes through publicly funded oncology systems, academic trial sites, and structured health technology assessment processes.

Europe benefits from EMA pathways, multinational cooperative research, and strong neuro-oncology centers across Germany, France, Italy, Spain, and the United Kingdom, although reimbursement timing varies by country. Asia-Pacific is expanding quickly as China, Japan, South Korea, Australia, and India strengthen oncology trial infrastructure, genomic medicine adoption, and specialist cancer care. Latin America, led by Brazil and Mexico, is improving access through specialty oncology centers and expanding private-sector diagnostics, while the Middle East shows rising demand in tertiary hospitals and national cancer programs. Africa remains more access-constrained, with availability shaped by neurosurgery capacity, pathology infrastructure, radiotherapy access, specialist availability, and reimbursement coverage.

Key Group Insights

The G7 markets remain highly influential because they combine advanced regulatory systems, reimbursement capacity, academic neuro-oncology expertise, and high participation in pivotal trials. The European Union supports cross-border research collaboration and centralized regulatory review, creating a structured pathway for innovative brain cancer drugs, although health technology assessment outcomes differ by member state. NATO-aligned markets generally benefit from mature health systems, interoperable research ecosystems, and strong academic oncology networks that support trial execution and evidence generation.

BRICS markets are strategically important for future patient access and clinical trial diversification, especially China, India, and Brazil, where cancer diagnostics, oncology infrastructure, and local innovation capacity are expanding. ASEAN is gaining relevance through Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines as specialist oncology services, private hospital networks, and molecular testing access improve. GCC countries are investing in advanced cancer care, national oncology strategies, international hospital partnerships, and medical tourism, creating stronger demand for precision brain cancer therapies in tertiary care settings.

Key Country Insights

The United States is the most active commercialization and research market for brain cancer drugs, supported by FDA expedited programs, orphan drug pathways, comprehensive cancer centers, and strong biotechnology funding. Canada provides high-quality trial participation, provincial cancer agencies, and structured public reimbursement review. Mexico and Brazil are important Latin American access markets, with Brazil offering the region’s largest oncology base and Mexico benefiting from proximity to North American clinical and regulatory ecosystems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist neuro-oncology care with national reimbursement processes, biomarker testing expansion, and established academic trial networks, while Russia presents a more complex access environment shaped by reimbursement, procurement, and geopolitical constraints. China is scaling domestic oncology innovation, regulatory reform, and brain tumor clinical trials; India has a large patient base and growing precision diagnostics in major metropolitan cancer centers; Japan and South Korea offer sophisticated regulatory systems, advanced imaging, and strong translational research; and Australia is a highly connected clinical trial market with internationally recognized cancer centers and robust neuro-oncology expertise.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined development strategies, robust CNS pharmacokinetic evidence, and combination designs that address tumor immune suppression, resistance, and recurrence. Development plans should incorporate MGMT, IDH, BRAF, H3 K27, EGFR alteration, TERT, 1p/19q codeletion, and other relevant markers early in clinical planning to improve patient selection, regulatory alignment, and payer confidence.

Commercial teams should prepare for evidence requirements beyond response rate, including progression-free survival, overall survival, neurocognitive outcomes, steroid-sparing benefit, seizure control, quality of life, and real-world durability. Partnerships with academic neuro-oncology centers, imaging AI vendors, diagnostic laboratories, contract research networks, and patient advocacy groups can accelerate enrollment, strengthen evidence generation, and improve market access readiness across advanced and emerging oncology systems.

Research Methodology

This executive summary is based on secondary research from verified public sources, including regulatory agency announcements, peer-reviewed oncology literature, clinical trial registries, cancer classification standards, treatment guidelines, and publicly available institutional research outputs. The analysis emphasizes data-backed developments such as approved therapies, recognized biomarkers, established standards of care, documented diagnostic trends, and regional access dynamics.

The methodology combines qualitative market assessment, therapeutic landscape review, regulatory tracking, regional access evaluation, and technology trend analysis. Findings were synthesized to support executive content while avoiding unsupported market sizing claims, speculative revenue estimates, market share statements, forecasting, or unverified clinical performance claims.

Conclusion

The brain cancer drugs market is entering a more precise, technology-enabled phase as molecular diagnostics, CNS-optimized therapies, and AI-supported development reshape the treatment pathway. Despite persistent challenges in glioblastoma and recurrent disease, recent targeted therapy approvals and biomarker-led trial designs show that clinically meaningful progress is accelerating.

Organizations that align discovery, clinical development, diagnostics, regulatory strategy, and market access will be best positioned to compete. The strongest opportunities will emerge where therapeutic innovation is paired with validated biomarkers, measurable patient outcomes, rigorous evidence generation, and equitable access across advanced and emerging oncology systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Brain Cancer Drugs Market, by Indication
7.1. Glioblastoma Multiforme
7.2. Meningioma
7.3. Metastatic Brain Tumors
7.4. Pituitary Tumors
8. Brain Cancer Drugs Market, by Drug Class
8.1. Chemotherapy
8.1.1. Alkylating Agents
8.1.2. Antimetabolites
8.1.3. Plant Alkaloids
8.2. Immunotherapy
8.2.1. Cancer Vaccines
8.2.2. CAR-T Therapy
8.2.3. Checkpoint Inhibitors
8.3. Supportive Therapy
8.3.1. Anti-Emetics
8.3.2. Growth Factors
8.4. Targeted Therapy
8.4.1. Monoclonal Antibodies
8.4.2. Tyrosine Kinase Inhibitors
9. Brain Cancer Drugs Market, by Route Of Administration
9.1. Intrathecal
9.2. Intravenous
9.3. Oral
10. Brain Cancer Drugs Market, by Treatment Modality
10.1. Monotherapy
10.2. Combination Therapy
11. Brain Cancer Drugs Market, by Drug Type
11.1. Branded
11.2. Generic
12. Brain Cancer Drugs Market, by End User
12.1. Clinics
12.2. Home Healthcare
12.3. Hospitals
13. Brain Cancer Drugs Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
14. Asia-Pacific Brain Cancer Drugs Market
15. Europe Brain Cancer Drugs Market
16. North America Brain Cancer Drugs Market
17. Latin America Brain Cancer Drugs Market
18. Africa Brain Cancer Drugs Market
19. Middle East Brain Cancer Drugs Market
20. NATO Brain Cancer Drugs Market
21. G7 Brain Cancer Drugs Market
22. BRICS Brain Cancer Drugs Market
23. European Union Brain Cancer Drugs Market
24. ASEAN Brain Cancer Drugs Market
25. GCC Brain Cancer Drugs Market
26. China Brain Cancer Drugs Market
27. United States Brain Cancer Drugs Market
28. Japan Brain Cancer Drugs Market
29. India Brain Cancer Drugs Market
30. Germany Brain Cancer Drugs Market
31. United Kingdom Brain Cancer Drugs Market
32. Australia Brain Cancer Drugs Market
33. France Brain Cancer Drugs Market
34. South Korea Brain Cancer Drugs Market
35. Italy Brain Cancer Drugs Market
36. Canada Brain Cancer Drugs Market
37. Russia Brain Cancer Drugs Market
38. Brazil Brain Cancer Drugs Market
39. Mexico Brain Cancer Drugs Market
40. Spain Brain Cancer Drugs Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. AbbVie Inc.
42.2. Amgen Inc.
42.3. Amneal Pharmaceuticals, Inc.
42.4. Arbor Pharmaceuticals, LLC
42.5. AstraZeneca PLC
42.6. Bayer AG
42.7. Bristol-Myers Squibb Company
42.8. Chimerix, Inc.
42.9. Day One Biopharmaceuticals, Inc.
42.10. DNAtrix, Inc.
42.11. Eisai Co., Ltd.
42.12. Eli Lilly and Company
42.13. Emcure Pharmaceuticals Limited
42.14. F. Hoffmann-La Roche Ltd
42.15. GlaxoSmithKline plc
42.16. Ipsen SA
42.17. Johnson & Johnson
42.18. Karyopharm Therapeutics Inc.
42.19. Kazia Therapeutics Limited
42.20. Merck & Co., Inc.
42.21. Merck KGaA
42.22. NextSource Pharmaceuticals, LLC
42.23. Novartis AG
42.24. Novocure GmbH
42.25. Pfizer Inc.
42.26. Servier Pharmaceuticals LLC
42.27. Sumitomo Pharma Co., Ltd.
42.28. Sun Pharmaceutical Industries Limited
42.29. Takeda Pharmaceutical Company Limited
42.30. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. NATO BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. NATO BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. GCC BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. GCC BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. JAPAN BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. INDIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. ITALY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CANADA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. MEXICO BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SPAIN BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MENINGIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MENINGIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MENINGIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PITUITARY TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PITUITARY TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PITUITARY TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-EMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-EMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-EMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 124. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 127. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 160. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 161. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 162. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 165. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 166. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. NATO BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 181. NATO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 182. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. NATO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 184. NATO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 185. NATO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 186. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 187. NATO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 189. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 190. NATO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. G7 BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 193. G7 BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 194. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 195. G7 BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 196. G7 BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 197. G7 BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 198. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 199. G7 BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 201. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 202. G7 BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 208. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 209. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 210. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 211. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 213. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 214. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 229. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 230. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 232. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 233. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 234. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 235. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 237. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 238. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. GCC BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 241. GCC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 242. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 243. GCC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 244. GCC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 245. GCC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 246. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 247. GCC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 249. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 250. GCC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 253. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 254. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 256. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 257. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 258. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 259. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 261. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 262. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. JAPAN BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 277. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 278. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 280. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 281. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 282. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 283. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 284. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 285. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 286. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 288. INDIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 289. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 290. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 291. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 292. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 293. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 294. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 295. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 296. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 297. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 298. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 299. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 300. GERMANY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 301. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 302. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 303. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 304. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 305. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 306. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 307. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 308. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 309. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 310. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 324. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 325. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 326. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 327. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 328. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 329. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 330. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 331. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 332. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 333. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 334. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 335. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 336. FRANCE BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 338. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 339. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 340. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 341. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 342. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 343. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 344. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 345. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 346. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 347. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 348. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 349. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 350. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 351. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 352. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 353. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 354. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 355. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 356. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 357. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 358. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 359. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 360. ITALY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 361. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 362. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 363. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD

Companies Mentioned

The companies featured in this Brain Cancer Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Arbor Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Chimerix, Inc.
  • Day One Biopharmaceuticals, Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • NextSource Pharmaceuticals, LLC
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Servier Pharmaceuticals LLC
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.03 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Brain Tumor Diagnosis & Therapeutics Market by Treatment Type, Diagnostic Modality, Tumor Type, Tumor Grade Type, Drug Class, Route of Administration, Application, End User, Patient Age Group - Global Forecast 2026-2032 - Product Image

Brain Tumor Diagnosis & Therapeutics Market by Treatment Type, Diagnostic Modality, Tumor Type, Tumor Grade Type, Drug Class, Route of Administration, Application, End User, Patient Age Group - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032 - Product Image

Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Pediatric Brain Cancer - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Pediatric Brain Cancer - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Ependymoma Market Report and Forecast 2025-2034 - Product Image

Ependymoma Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Malignant Glioma Therapeutics - Global Strategic Business Report - Product Image

Malignant Glioma Therapeutics - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From

About the Brain Cancer Drugs Market

The Brain Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat brain cancer. Brain cancer is a type of cancer that affects the cells of the brain and can be caused by a variety of factors, including genetics, environmental exposure, and lifestyle. Brain cancer drugs are used to treat the symptoms of brain cancer, such as headaches, seizures, and nausea, as well as to slow the progression of the disease. Brain cancer drugs are typically divided into two categories: chemotherapy and targeted therapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are designed to target specific cancer cells and stop them from growing. Both types of drugs are used in combination to treat brain cancer. Some of the major companies in the Brain Cancer Drugs market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. These companies are involved in the development and sale of drugs used to treat brain cancer, as well as in the research and development of new treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.